• Denis Getsios, Yamei Wang, Marilyn Stolar, Greg Williams, K Jack Ishak, Ming-yi Hu, Piedad Alvarez, and Tracy Aber Crothers.
• United BioSource Corp., 430 Bedford Street, Suite 300, Lexington, MA 02420, USA. denis.getsios@unitedbiosource.com
• Expert Opin Pharmacother. 2013 Jul 1; 14 (10): 1285-93.

BackgroundPerioperative hypertension affects 80% of cardiac surgery patients and is associated with an increased risk of complications.ObjectiveTo determine the relationship between perioperative blood pressure (BP) control and hospital costs for cardiac surgery in the United States (US) and estimate the potential cost reductions associated with effective therapies.MethodsThe analysis estimated hospitalization costs (2011 US dollars (USD)) for cardiac surgery when BP was controlled with intravenous (IV) antihypertensives. Patient characteristics, hospital length of stay, and clinical event rates during the initial hospitalization and post-discharge 30 days after study drug infusion were based on the ECLIPSE (Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events) trials. These clinical trial data were combined with data from the Massachusetts Acute Hospital Case Mix Database 2007 - 2009 (MA Case Mix Database) to estimate total hospitalization costs.ResultsEffective perioperative BP control in patients requiring IV antihypertensives was associated with a 7% decrease in hospital costs compared with less effective BP control. Reductions in total hospital costs associated with clevidipine versus other IV antihypertensives averaged $394 per patient overall. Cost savings with clevidipine exceeded $500 per patient versus sodium nitroprusside and nitroglycerin, but only $22 compared to nicardipine.ConclusionImproved perioperative BP control may reduce hospital costs. Given the low cost of IV antihypertensives, the total hospital cost reductions may offset any incremental cost increases associated with newer, more effective therapies.

17 keywords...

hide…